Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 31722-337

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 31722-337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pemetrexed100cartonlabel (Pemetrexed100cartonlabel)

This text includes information about Pemetrexed for Injection, USP, with a dosage of 100 mg for intravenous use only. It provides details such as batch coding, expiration date, lot number, and 2D DataMatrix contents for tracking and identification. The product is labeled as a cytotoxic agent and manufactured by HETERO LABS LIMITED in India. Contact information for US inquiries is also provided for Camber Pharmaceuticals, Inc. in Piscataway, NJ.*

FDA Label Image

Pemetrexed100viallabel (Pemetrexed100viallabel)

This is a cautionary label for a cytotoxic agent containing pemetrexed disodium. The vial should be stored at 25°C (77F) with excursions permitted between 15° to 30°C (59° to 86°F). It is for intravenous use only and should be kept at controlled room temperature. The manufacturer is Hetero Labs Limited, and the product is distributed by Camber Pharmaceuticals, Inc.*

FDA Label Image

Pemetrexed500cartonlabel (Pemetrexed500cartonlabel)

This text provides information about Pemetrexed, a medication that is meant for intravenous use only. It is stated to be a single-dose vial and labeled as a cytotoxic agent, indicating it is used for treating certain types of cancer. The contact number for the US manufacturer is provided along with details about the manufacturer in India. Additional details such as lot number and dosage information are also present.*

FDA Label Image

Pemetrexed500viallabel (Pemetrexed500viallabel)

This text is a label for the prescription drug Pemetrexed for Injection, USP. The medication is a cytotoxic agent used for intravenous administration only. Each vial contains pemetrexed disodium equivalent to 500 mg pemetrexed, along with 500 mg of mannitol. The label provides storage instructions, manufacturer details, and a contact number for the United States. It also warns to discard any unused portion of the medication. The details in the text are crucial for healthcare professionals and patients using this medication.*

FDA Label Image

Pemetrexedfigure1 (Pemetrexedfigure1)

FDA Label Image

Pemetrexedfigure10 (Pemetrexedfigure10)

FDA Label Image

Pemetrexedfigure2 (Pemetrexedfigure2)

This is a survival probability graph comparing the treatments Pemetrexed for Injection + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The x-axis represents survival time in months and the y-axis represents the survival probability. The data shows the number of patients at risk at different time points.*

FDA Label Image

Pemetrexedfigure3 (Pemetrexedfigure3)

This is a survival probability graph comparing Pemetrexed for Injection + Cisplatin (AC) versus Gemcitabine + Cisplatin (GC) over a span of 30 months. The graph displays the number of patients at risk for each treatment option at different time intervals, showing the survival time in months.*

FDA Label Image

Pemetrexedfigure4 (Pemetrexedfigure4)

This is a table showing survival time in months for patients receiving two different treatments, Pemetrexed for Injection + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The number of patients at risk is also provided for both treatment groups at different time intervals ranging from 3 to 30 months.*

FDA Label Image

Pemetrexedfigure5 (Pemetrexedfigure5)

This data represents the survival probability curve for patients treated with Pemetrexed for Injection compared with those on a placebo. The graph displays the survival time in months on the x-axis, with patients at risk shown at different time intervals for each treatment group.*

FDA Label Image

Pemetrexedfigure6 (Pemetrexedfigure6)

This data table shows the survival probability for patients using Pemetrexed for Injection over a period of 42 months compared to a control group receiving a placebo. The number of patients at risk and their survival time in months is provided at different time intervals. This information can be useful for evaluating the effectiveness of Pemetrexed in prolonging patient survival.*

FDA Label Image

Pemetrexedfigure7 (Pemetrexedfigure7)

This appears to be a table representing survival probability over time for patients at risk in a study comparing Pemetrexed for Injection to placebo. The survival probabilities are shown at various time points in months for both the treatment group and the placebo group. The data suggests that Pemetrexed for Injection may have a positive effect on survival compared to placebo.*

FDA Label Image

Pemetrexedfigure8 (Pemetrexedfigure8)

This data represents the survival probabilities of patients treated with Pemetrexed for Injection compared to those who received a Placebo over a 36-month period. The graph shows survival times in months for both treatment groups. Patients receiving Pemetrexed for Injection had higher survival rates compared to those who received a Placebo.*

FDA Label Image

Pemetrexedfigure9 (Pemetrexedfigure9)

This is a survival probability chart comparing patients treated with Pemetrexed for Injection + Cisplatin versus those treated with Cisplatin. It shows the survival time in months and the number of patients at risk at different time intervals.*

FDA Label Image

Pemetrexedstructure (Pemetrexedstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.